Trials / Completed
CompletedNCT01104415
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telotristat etiprate | Telotristat etiprate capsules orally three times daily. |
Timeline
- Start date
- 2010-06-15
- Primary completion
- 2014-02-12
- Completion
- 2014-02-12
- First posted
- 2010-04-15
- Last updated
- 2019-03-15
- Results posted
- 2018-04-06
Locations
10 sites across 2 countries: Germany, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01104415. Inclusion in this directory is not an endorsement.